AEterna Zentaris Announces Closing of Secondary Offering of Shares of Atrium Biotechnologies Inc.
October 18 2006 - 9:23AM
PR Newswire (US)
QUEBEC CITY, Oct. 18 /PRNewswire-FirstCall/ -- AEterna Zentaris
Inc. (TSX: AEZ; NASDAQ: AEZS), a growing global biopharmaceutical
company focused on endocrine therapy and oncology, announced today
that it has closed its previously announced secondary offering of
its 3,485,000 subordinate voting shares of Atrium Biotechnologies
Inc., at a price of Cdn$15.80 per share. Concurrent with the
closing of the secondary offering and in accordance with the
articles of Atrium Biotechnologies, AEterna Zentaris' remaining
multiple voting shares have been converted into subordinate voting
shares of Atrium Biotechnologies such that AEterna Zentaris now
owns 11,052,996 subordinate voting shares representing
approximately 36.1% of the issued and outstanding shares of Atrium
Biotechnologies. As previously announced, prior to the end of 2006,
AEterna Zentaris intends, subject to receiving regulatory and other
approvals, to distribute all of its remaining 11,052,996
subordinate voting shares of Atrium to its shareholders. This press
release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities in any jurisdiction. The
subordinate voting shares of Atrium Biotechnologies have not been,
and will not be, registered under the U.S. Securities Act of 1933,
as amended, or any state securities laws, and may not be offered or
sold in the United States absent registration or an applicable
exemption from registration requirements. About AEterna Zentaris
Inc. AEterna Zentaris Inc. is a growing global biopharmaceutical
company focused on endocrine therapy and oncology with proven
expertise in drug discovery, development and commercialization.
News releases and additional information are available at
http://www.aeternazentaris.com/. DATASOURCE: AETERNA ZENTARIS INC.
CONTACT: Media Relations: Paul Burroughs, (418) 652-8525 ext. 406,
; Investor Relations: Jenene Thomas, (418) 655-6420, (908)
996-3154,
Copyright